Merck, known as MSD outside the US and Canada, has won Zetia (ezetimibe) / Vytorin (ezetimibe/simvastatin) patent infringement suits against Mylan Pharmaceuticals.
The US District Court has ruled in favor of Merck in two jointly related patent infringement suits.
Merck general counsel and executive vice president Bruce Kuhlik said, "The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid and enforceable."
The court ruled that Merck's patent on ZETIA and VYTORIN was valid and even issued an order blocking approval of Mylan's generic versions until the expiration of the patent.
The patent at issue in this trial is RE 42,461 which covers ezetimibe, an active ingredient in both ZETIA and VYTORIN and expires April 2017, Merck said.
Sidley Austin LLP, Lowenstein Sandler PC and Robinson, Wettre & Miller LLC represented Merck.
